Status:
TERMINATED
Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Schizophrenia
Eligibility:
MALE
18-70 years
Phase:
PHASE1
Brief Summary
This is a brief inpatient study to determine the safety of a new drug in healthy people.
Detailed Description
AVL-3288, a "first in class" small molecule, selective allosteric modulator of the α7 nAChR, is implicated in the cognitive deficit in patients with neurologic and psychiatric disorders, including sch...
Eligibility Criteria
Inclusion
- Healthy volunteer
Exclusion
- Substance use. We do not accept inquiries by email.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01851603
Start Date
June 1 2013
End Date
August 1 2016
Last Update
December 30 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U of Colorado Denver
Aurora, Colorado, United States, 80045